AgriStability enrolment deadline extended to July 31, 2025

Apr 25, 2025

Given the pressures and uncertainties facing the agricultural sector, federal, provincial and territorial governments have agreed to extend the AgriStability enrolment deadline from April 30, 2025, to July 31, 2025, for the 2025 program year.

AgriStability is a margin-based program designed to help producers manage large income declines. This extension gives producers additional time to consider their needs and manage the impact of challenges faced by many farm operations, such as production loss, increased costs and changing market conditions. Farmers experiencing losses are encouraged to apply for interim payments under AgriStability for more rapid support.

Producers have access to a comprehensive suite of business risk management (BRM) programs, including AgriStability, to help manage significant risks that threaten the viability of their farms and are beyond their capacity to manage. BRM programs are often the first line of support for producers facing disasters. Farmers are encouraged to make use of these programs to protect their farming operation and contribute to a more resilient Canadian agriculture sector.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.